Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

8 May 2006 12:34

Quintessentially English PLC08 May 2006 Quintessentially English plc (the 'Company' or 'Quintessentially') Result of AGM and AGM statement The Board of Quintessentially English plc (the "Company") announces that at theAnnual General Meeting of the Company held earlier today, Resolutions 1 to 5 were duly approved by Shareholders. Resolutions 6 and 7 authorising the Directors to allot securities up to amaximum nominal amount of £388,250 and disapply pre-emption rights on theallotment of up to £388,250 of relevant securities were withdrawn in view of thefact that the Company's shares are now suspended from trading on AIM and thatany further issue of shares is likely to constitute a reverse takeover andtherefore would require prior shareholder approval. The Board also notedtechnical discrepancies in relation to the drafting of these resolutions. At the conclusion of the meeting the Board made the following statement: "Since the suspension of trading of the Company's shares on AIM on 1 April 2006,the Board has continued to seek a suitable reverse acquisition for the Company.A number of interesting opportunities are currently being explored. The Boardwill keep shareholders abreast of progress. Following the posting of the annual report and accounts to shareholders inApril, the Board wishes to clarify the accounts in relation to the steps theboard intends to take in the event that no acquisition constituting a reversetakeover is made by 1 October 2006 and, as specified by the London StockExchange, trading in the Company's shares on AIM is cancelled. If thiseventuality arises, it is the Board's intention to seek a quotation for theCompany's shares on an alternative exchange, subject to Shareholder approval. Furthermore, in order to maximise the attractiveness of the Company as anacquisition vehicle, each of the Directors has agreed to vary the terms of theirservice contracts fixing their remuneration, such that their remuneration willnow be agreed at the time of a reverse acquisition." This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Oct 20197:00 amRNSTrading Update and Notice of Interim Results
15th Oct 20192:29 pmRNSHolding(s) in Company
14th Oct 20198:18 amRNSHolding(s) in Company
14th Oct 20197:00 amRNSHolding(s) in Company
11th Oct 20198:00 amRNSHolding(s) in Company
10th Oct 201910:30 amRNSResult of General Meeting
27th Sep 201910:00 amRNSNotice of AGM and posting of annual report
23rd Sep 20197:01 amRNSPlacing & Subscription, Notice of General Meeting
23rd Sep 20197:00 amRNSFinal Results
16th Sep 20197:00 amRNSUpdate on VISITECT® CD4 Advanced Disease
10th Sep 20197:00 amRNSPurchase Order for Chinese Food Detective® test
20th Aug 20197:00 amRNSFirst VISITECT® CD4 Advanced Disease Test Order
16th Aug 201911:00 amRNSRe. Results, Trading Update & Nigerian CD4 Order
8th Aug 20197:00 amRNSInvestor Briefing
6th Jun 20197:00 amRNSAnnouncement of Results
5th Jun 20191:37 pmRNSHolding(s) in Company
3rd Jun 20191:43 pmRNSHolding(s) in Company
22nd May 20197:00 amRNSSubscription to raise c.£635,000
17th Apr 20197:00 amRNSTrading Update
18th Mar 20197:00 amRNSCE-Mark for VISITECT® CD4 Advanced Disease test
6th Mar 20197:00 amRNSVISITECT® CD4 update
1st Mar 20197:00 amRNSBoard Appointment
29th Jan 20197:00 amRNSVISITECT® CD4 Advanced Disease test update
10th Dec 20189:00 amRNSDirectorate Change
3rd Dec 20187:00 amRNSInterim results
19th Oct 20184:27 pmRNSHolding(s) in Company
10th Oct 20187:00 amRNSTrading Update and Notice of Interim Results
8th Oct 20182:38 pmRNSHolding(s) in Company
27th Sep 20187:00 amRNSAllergy CE-Mark and first Purchase Order
14th Sep 201811:25 amRNSResult of AGM
10th Sep 20188:56 amRNSHolding(s) in Company
6th Aug 20187:01 amRNSFinal Results
6th Aug 20187:00 amRNSVISITECT® CD4 Advanced Disease Development Update
30th Jul 20185:29 pmRNSHolding(s) in Company
18th Jul 20187:00 amRNSVISITECT® CD4 commercialisation update
12th Jul 20187:00 amRNSInvestor results presentation
2nd Jul 20187:00 amRNSNotice of Results
28th Jun 20187:00 amRNSDisposal of infectious disease business
21st May 20187:00 amRNSVISITECT CD4 development update
8th May 20187:00 amRNSAllersys? CE-Mark
2nd May 20187:41 amRNSClosure of Omega Diagnostics GmbH
24th Apr 20185:04 pmRNSPDMR Dealing
24th Apr 20187:00 amRNSHolding(s) in Company
23rd Apr 20183:50 pmRNSHolding(s) in Company
23rd Apr 20182:24 pmRNSDirector/PDMR Shareholding
23rd Apr 20182:22 pmRNSHolding(s) in Company
23rd Apr 20189:31 amRNSDirector/PDMR Shareholding
20th Apr 20187:00 amRNSAllersys Distribution Agreement
19th Apr 201811:45 amRNSInvestor Evening
10th Apr 20184:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.